title: Pronounced response of papillary craniopharyngioma to treatment with vemurafenib, a BRAF inhibitor.
authors.affiliation: Department of Endocrinology, King's College Hospital, London, SE5 9RS, UK. simonaylwin@nhs.net.
authors.forename: Simon J B
authors.initials: SJ
authors.lastname: Aylwin
authors.affiliation: Department of Clinical Neuropathology, King's College Hospital, London, UK.
authors.forename: Istvan
authors.initials: I
authors.lastname: Bodi
authors.affiliation: Department of Neuro-oncology, Guy's & St Thomas' Hospital Cancer Centre, London, UK.
authors.forename: Ronald
authors.initials: R
authors.lastname: Beaney
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D003397:Craniopharyngioma / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D005260:Female; D006801:Humans; D007211:Indoles / Q000494:pharmacology / Q000627:therapeutic use*; D010902:Pituitary Gland / Q000473:pathology; D010911:Pituitary Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D048493:Proto-Oncogene Proteins B-raf / Q000037:antagonists & inhibitors* / Q000235:genetics; D013449:Sulfonamides / Q000494:pharmacology / Q000627:therapeutic use*; D000077484:Vemurafenib
chemical_list: D000970:Antineoplastic Agents; D007211:Indoles; D013449:Sulfonamides; D000077484:Vemurafenib; C482119:BRAF protein, human; D048493:Proto-Oncogene Proteins B-raf